Limits...
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.

- Drugs R D (2010)

Bottom Line: Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis.This drug is currently in phase III development.This review discusses the development history and scientific profile of this new compound.

View Article: PubMed Central - PubMed

ABSTRACT
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific profile of this new compound.

Show MeSH

Related in: MedlinePlus

Forecasts
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585985&req=5

Tab3: Forecasts


Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.

- Drugs R D (2010)

Forecasts
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585985&req=5

Tab3: Forecasts
Bottom Line: Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis.This drug is currently in phase III development.This review discusses the development history and scientific profile of this new compound.

View Article: PubMed Central - PubMed

ABSTRACT
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific profile of this new compound.

Show MeSH
Related in: MedlinePlus